Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Chief
Urologic Oncology Branch
Senior Investigator
Dr. Linehan pioneered the study of the genetic basis of kidney cancer. His team identified the genes for the common forms of kidney cancer and described the pathways of these kidney cancer genes. His recent studies targeting the metabolic basis of kidney cancer have resulted in the regression of metastatic cancer in patients with type 1 and type 2 papillary kidney cancer.
As Chief, Dr. Linehan oversees the Branch’s clinical/translational research program, which emphasizes new approaches to the therapies of genitourinary cancers, diagnostic and prognostic evaluation of solid GU tumors, and the development of innovative surgical and adjunctive approaches to the treatment of patients with primary and metastatic urologic cancer.
Areas of Expertise
1) VHL gene, 2) targeted therapy, 3) metabolic therapy, 4) clear cell kidney cancer, 5) papillary kidney cancer
Molecular and Genetic Medicine received 3919 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 